Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
Retrieved on:
Tuesday, October 5, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Mortality, PCR, Medical microbiology, Clinical trial, Assistant, Inflammatory Bowel Diseases, Orphan, Diagnosis, Recurrence, Infection, Therapy, United States Department of Health and Human Services, Doctor of Philosophy, Biomedical Advanced Research and Development Authority, Patient, Death, Population, Feces, BARDA, HHS, Development, MSU MFA Program in Science & Natural History Filmmaking, University, Disease, Odds ratio, Bacteria, Immune system, List of life sciences, Contract manufacturing organization, PRTC, LSE, CDI, Risk, Food allergy, Cell, Office of the Assistant Secretary for Preparedness and Response, Research, LBP, PureTech Health, Safety, Data analysis, Clostridioides difficile infection, Department, Pharmaceutical industry, Medical device, Antibiotics, VE303, Vedanta Biosciences, VE303, VEDANTA BIOSCIENCES
We believe these results are an important step forward for the prevention of C. difficile infection and the microbiome field at large.
Key Points:
- We believe these results are an important step forward for the prevention of C. difficile infection and the microbiome field at large.
- Recurrent CDI causes approximately half a million infections each year in the United States, including up to 165,000 recurring infections and up to 45,000 deaths.
- Based on the Phase 2 data, BARDA has exercised its first contract option for additional funding of $23.8 million pursuant to its existing 2020 contract with Vedanta.
- Total committed funding under the BARDA award to date is $31.2 million, inclusive of this first contract option.